Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.56 |
| ▸ | KDM5A | P29375 | 12/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17507004 | 0.96 | MAP3K12 (0.51) | MAP3K12KDM5AKDM4CKDM5C | |
| SCHEMBL17507037 | 0.84 | MAP3K12 (0.45) | MAP3K12 | |
| SCHEMBL16220223 | 0.80 | MAP3K12 (0.71) | MAP3K12 | |
| SCHEMBL17507081 | 0.78 | MAP3K12 (0.61) | MAP3K12 | |
| SCHEMBL17507062 | 0.78 | MAP3K12 (0.55) | MAP3K12 | |
| SCHEMBL16220516 | 0.77 | MAP3K12 (0.91) | MAP3K12 | |
| SCHEMBL17507042 | 0.77 | MAP3K12 (0.51) | MAP3K12 | |
| SCHEMBL16220047 | 0.76 | MAP3K12 (0.78) | MAP3K12 | |
| SCHEMBL17507026 | 0.74 | MAP3K12 (0.49) | MAP3K12 | |
| SCHEMBL17507075 | 0.74 | MAP3K12 (0.46) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | TYMS, DPYD, TYMP | MAP3K12 1825/4885KDM5A 2340/4885KDM4C 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.